[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541169":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":34,"collaborators":24,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":24,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":24,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":24,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":24},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"autologous stromal vascular fraction derived from denovo","ACTIVE_COMPARATOR","autologous stromal vascular fraction derived from denovo in male androgenic alopecia",[13],"Procedure: autologous stromal vascular fraction",{"label":15,"type":10,"description":16,"interventionNames":17},"autologous stromal vascular fraction after platelet rich plasma enhanced donner site","autologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","autologous stromal vascular fraction","autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval",[15,9],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"dina A mahmoud, assistant lecturer","CONTACT","01097185631","dr.dondon123@gmail.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":24},"reham E Elsharkawy, Professor","01006809003",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Dina Ahmed Mahmoud","assistant lecturer","100541169","autologous-stromal-vascular-fraction-in-treatment-of-male-androgenic-alopecia-100541169",false,"NCT06326359","Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia","Evaluation of Safety and Efficacy of Autologous Stromal Vascular Fraction Derived From Denovo Versus Platelet Rich Plasma Enhanced Donner Site in Treatment of Male Androgenic Alopecia","Inclusion Criteria:\n\n* Male patients with androgenic alopecia\n\nExclusion Criteria:\n\n* Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.\n\nAny other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area.\n\nAny systemic disease as autoimmune disorders , cardiac hepatic and renal patients.\n\npatients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study",true,"MALE","18 Years","55 Years",{"count":50,"type":51},40,"ESTIMATED","INTERVENTIONAL",[54],"NA","Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia",[57],"Androgenic Alopecia",[21,59,60],"platelet rich plasma","male androgenic alopecia","NOT_YET_RECRUITING","2024-03-16",{"date":64,"type":65},"2024-03-22","ACTUAL",{"date":67,"type":51},"2024-03",{"date":69,"type":51},"2026-10",{"name":5,"class":6}]